Free Trial
NASDAQ:TVRD

Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Tvardi Therapeutics logo
$28.05 +1.40 (+5.25%)
As of 08/22/2025 04:00 PM Eastern

About Tvardi Therapeutics Stock (NASDAQ:TVRD)

Key Stats

Today's Range
$26.74
$29.00
50-Day Range
$21.45
$29.83
52-Week Range
$8.13
$34.31
Volume
42,712 shs
Average Volume
22,521 shs
Market Capitalization
$263.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.25
Consensus Rating
Buy

Company Overview

Tvardi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

TVRD MarketRank™: 

Tvardi Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 819th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tvardi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tvardi Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Tvardi Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Tvardi Therapeutics has a P/B Ratio of 7.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for TVRD.
  • Dividend Yield

    Tvardi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tvardi Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for TVRD.
  • News Sentiment

    Tvardi Therapeutics has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Tvardi Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for TVRD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Tvardi Therapeutics is held by insiders.

  • Percentage Held by Institutions

    44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tvardi Therapeutics' insider trading history.
Receive TVRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TVRD Stock News Headlines

BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More Headlines

TVRD Stock Analysis - Frequently Asked Questions

Tvardi Therapeutics' stock was trading at $29.09 at the beginning of the year. Since then, TVRD shares have decreased by 3.6% and is now trading at $28.05.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) announced its earnings results on Thursday, August, 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.49. Tvardi Therapeutics had a negative trailing twelve-month return on equity of 565.83% and a negative net margin of 595.39%.

Tvardi Therapeutics' top institutional shareholders include Slate Path Capital LP (7.52%), 683 Capital Management LLC (1.88%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.27%).

Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2025
Today
8/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TVRD
Previous Symbol
NASDAQ:TVRD
CIK
1346830
Web
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$78.00
Low Price Target
$52.00
Potential Upside/Downside
+129.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$70.87 million
Net Margins
-595.39%
Pretax Margin
-453.48%
Return on Equity
-565.83%
Return on Assets
-66.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.04
Quick Ratio
31.73

Sales & Book Value

Annual Sales
$7.14 million
Price / Sales
36.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.51 per share
Price / Book
7.99

Miscellaneous

Outstanding Shares
9,380,000
Free Float
9,086,000
Market Cap
$263.11 million
Optionable
N/A
Beta
0.21
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TVRD) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners